We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results:1-10 of 18

Health select committee report on NICE
  • Mills & Reeve LLP
  • United Kingdom
  • February 4 2013

The recently published Health Select Committee report on the activities of NICE reflects on how it has performed in a number of areas and touches on


NICE to advise on unlicensed and off-label drugs for rare and other diseases
  • Mills & Reeve LLP
  • United Kingdom
  • November 8 2011

The DH has announced that it is to take steps to build a better evidence base for situations where near-label treatment is appropriate, with the intention of improving clinical practice and the consistency of care offered to patients with rare conditions.


Government responds to consultation on value-based pricing
  • Mills & Reeve LLP
  • United Kingdom
  • August 8 2011

Just before Christmas last year, the Government published a consultation paper on a new “value-based” pricing (VBP) system for pharmaceuticals which will replace the Pharmaceutical Price Regulation Scheme (PPRS) currently in operation and due to expire at the end of 2013.


Rarer Cancers Foundation reports on operation of Cancer Drugs Fund
  • Mills & Reeve LLP
  • United Kingdom
  • July 18 2011

The Rarer Cancers Foundation has published a progress report on the effect of the Cancer Drugs Fund (the fund) in its first six months of operation, entitled Funding Cancer Drugs: An evaluation of the impact of policies to improve access to cancer treatments.


Department of Health issues guidance to support the operation of the Cancer Drugs Fund 2011-12
  • Mills & Reeve LLP
  • United Kingdom
  • April 14 2011

The Department of Health has produced guidance to the NHS, on the operation of the Cancer Drugs Fund (the fund) for the period 2011 to 2012, intended primarily for strategic health authorities (SHAs) and their clinically-led panels: The Cancer Drugs Fund: Department of Health - publications.


The Cancer Drugs Fund: £200 million new money? Old money? Whose money?
  • Mills & Reeve LLP
  • United Kingdom
  • April 14 2011

A letter to strategic health authority (SHA) medical directors from Sir Bruce Keogh has led to allegations that the Department of Health has reneged on its pledge to provide extra money for cancer drugs via the Cancer Drugs Fund.


Patient matters: provision of medicines - eye is for ‘institute’: NICE reports back on the feasibility of appraising Avastin for wet AMD
  • Mills & Reeve LLP
  • United Kingdom
  • January 21 2011

As we reported in last June's edition of the Health legal update, the National Institute for Health and Clinical Excellence (NICE) has been asked by the Department of Health (DH) to look into the possibility of appraising the clinical and cost effectiveness of bevacizumab (Avastin) to treat wet age-related macular degeneration, the leading cause of blindness in the UK, and other conditions affecting the eye.


NHS organisations to be named in report into the uptake of nice-approved drugs on the NHS
  • Mills & Reeve LLP
  • United Kingdom
  • October 15 2010

The National Institute for Health and Clinical Excellence (NICE) has announced that its second report, on the uptake of medicines which it has positively appraised, will this time name the strategic health authorities, primary care trusts and cancer networks involved.


New £50million interim cancer drugs fund announced
  • Mills & Reeve LLP
  • United Kingdom
  • September 7 2010

Ministers have announced a £50million interim cancer drugs fund ahead of the creation of the fully-fledged fund giving effect to the Conservative election manifesto promise, expected to be implemented in April 2011.


Guidance issued to ensure more uniform provision of newly licensed drugs north of the border
  • Mills & Reeve LLP
  • United Kingdom
  • June 14 2010

Guidance on the introduction of newly licensed medicines has been issued to Health Board Chief Executives by the Healthcare Policy and Strategy Directorate of the Scottish Government.